LIDDS

LIDDS

Market Cap 403.4M

LIDDS är ett Uppsalabaserat bolag som använder teknologiplattformen NanoZolid för att utveckla läkemedelskandidater. NanoZolid är en depot-lösning som kan integrera både små och stora molekyler vilket ger möjlighet till lokal behandling med fördröjd frisättning och lägre systemisk effekt av läkemedlet. Affärsmodellen går ut på att dels utveckla egna projekt för utlicensiering till en partner och dels att tillsammans med en partner utveckla nya läkemedelskandidater. Huvudfokus ligger på generika, beprövade och bevisade substanser som kan utvecklas ytterligare med en förbättrad administreringsmetod i NanoZolid.  Det längst framskridna projektet är Liproca Depot, baserat på 2-hydroxyflutamide, vilken utvecklas inom prostatacancer och för närvarande studeras i en fas IIb. Flera andra projekt utvecklade från NanoZolid-plattformen finns i pipeline, bland andra med cytostatika och antikroppar. Avtal har även skrivits med Ferring Pharmaceuticals och Belina Pharma för utvecklandet av cancerläkemedel. 

+ more

Redeye Research

Reports

Notes

Today
Day High
17.75
17.5
Day Low
17.35
Day Open
17.45
Prev Close
17.50
VWAP
17.5
Volume
35K
Turnover
0.612M
Top Broker
VWAP
17.5
Avg Volume
47K
Avg Turnover
0.815M
Top Brokers
NON/AVA
VWAP
18.0
Avg Volume
38K
Avg Turnover
0.680M
Top Brokers
NON/AVA
VWAP
18.7
Avg Volume
56K
Avg Turnover
1.038M
Top Brokers
AVA/NON
52 week summary
Price Range
6.4
Last
23.1
Beta
N/A
Market Cap
403.4M
Total Return
173.4%
Trailing P/E
-57.3
Div Yield
0.0%
Shares Outstanding
23.1M
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months 18.7%
Change 12 Months 190.3%
Volume Trend
Average Volume 10 vs 60 Days -44.6%
Price VS
52 Week High -24.2%
50 Day Moving Average -2.3%
200 Day moving Average 9.4%

Add article markers

Compare LIDDS to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Monica Wallter, CEO
  • Bengt Norvik, CFO
  • Executive board
  • Jan Törnell, Chairman of the board
  • Inga-Lill Forslund Larsson
  • Anders Bjartell
  • Maria Forss
  • Daniel Lifveredson
Last updated: 2017-11-16 Source: Redeye
Major Owners Equity Votes
Lars Wikander 8.9%
8.9%
Avanza Pension 8.1%
8.1%
Daniel Lifveredson (Inkl. Bolag) 7.7%
7.7%
Swedbank Försäkring 6.8%
6.8%
Nyenburgh Holding B.V. 4.2%
4.2%
Bengt Sporre 4.2%
4.2%
Recipharm Venture Fund AB 3.3%
3.3%
Henry Dunkers Donationsfond & Stiftelser 2.7%
2.7%
Gunvald Berger 2.6%
2.6%
Peter Thelin 1.8%
1.8%
Last updated: 2018-05-31 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
1 Purchases
3,000
0 Sales
0
Last 24 weeks
1 Purchases
3,000
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • -8.0%
  • -8.0%
  • -10.0%
  • 0.0%
  • 0.0%
  • 0.0%
  •  
  • -0.57
  • -0.57
  • 0.00
  •  
  • 13.7
  •  
  • 94.3
  • -14.1
  • -14.1
  • 0.0
  • 0.0
  • -12.0
  • -12.0
  • 1.1
  •  
  • 97.5%
  • 0.0%
  • -15
  • 84
  • 0.0
  • 2015
  •  
  •  
  • 15
  • 0
  • 0
  • 0
  • 16
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 86
  • 0
  • 86
  • 0
  • 102
  •  
  •  
  • 0
  • 3
  • 0
  • 3
  • 0
  • 0
  • 0
  • 3
  • 0
  • 0
  • 100
  • 0
  • 100
  • 102
  • 2015
  • 0
  • -8
  • 0
  • -8
  • 0
  • -8
  • 0
  • -8
  • 0
  • -6
  • -14
  • 2015 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 0
  • -8
  • -8
  • 0
  • 0
  • 0
  • -8
  • 0
  • 0
  • 0
  • -8
  • 0
  • -8
  • 2016
  •  
  • -6.2%
  • -6.3%
  • -7.9%
  • -165,854.0%
  • -165,854.0%
  • -163,879.0%
  •  
  • -0.37
  • -0.37
  • 0.00
  •  
  • 17.6
  •  
  • -18.7
  • 0.0
  • 0.0
  • 0.0
  • -4,670.2
  • 2.8
  • 2.8
  • 0.0
  •  
  • 93.0%
  • 0.0%
  • -19
  • 94
  • 0.0
  • 2016
  •  
  •  
  • 19
  • 2
  • 0
  • 1
  • 21
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 100
  • 0
  • 100
  • 0
  • 121
  •  
  •  
  • 0
  • 8
  • 0
  • 8
  • 0
  • 0
  • 0
  • 8
  • 0
  • 0
  • 113
  • 0
  • 113
  • 121
  • 2016
  • 0
  • -7
  • 0
  • -7
  • 0
  • -7
  • 0
  • -7
  • 5
  • -14
  • -16
  • 2016 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q4
  • 0
  • -7
  • -7
  • 0
  • 0
  • 0
  • -7
  • 0
  • 0
  • 0
  • -7
  • 0
  • -7
  • 2017
  •  
  • -5.6%
  • -5.6%
  • -7.1%
  • -167,075.0%
  • -167,075.0%
  • -166,950.0%
  •  
  • -0.31
  • -0.31
  • 0.00
  •  
  • 21.9
  •  
  • -15.3
  • 0.0
  • 0.0
  • 0.0
  • -3,821.5
  • 2.3
  • 2.3
  • 0.0
  •  
  • 97.3%
  • 0.0%
  • -15
  • 112
  • 0.0
  • 2017
  •  
  •  
  • 15
  • 0
  • 0
  • 1
  • 17
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 114
  • 0
  • 114
  • 0
  • 131
  •  
  •  
  • 0
  • 4
  • 0
  • 4
  • 0
  • 0
  • 0
  • 4
  • 0
  • 0
  • 127
  • 0
  • 127
  • 131
  • 2017
  • 0
  • -7
  • 0
  • -7
  • 0
  • -7
  • 0
  • -7
  • -4
  • -14
  • -25
  • 2017 Q1
  • 0
  • -2
  • -2
  • 0
  • 0
  • 0
  • -2
  • 0
  • 0
  • 0
  • -2
  • 0
  • -2
  • 2017 Q2
  • 0
  • -1
  • -1
  • 0
  • 0
  • 0
  • -1
  • 0
  • 0
  • 0
  • -1
  • 0
  • -1
  • 2017 Q3
  • 0
  • -1
  • -1
  • 0
  • 0
  • 0
  • -1
  • 0
  • 0
  • 0
  • -1
  • 0
  • -1
  • 2017 Q4
  • 0
  • -2
  • -2
  • 0
  • 0
  • 0
  • -2
  • 0
  • 0
  • 0
  • -2
  • 0
  • -2
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 Q1 E
  • 2018 Q2 E
  • 2018 Q3 E
  • 2018 Q4 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 Q1 E
  • 2019 Q2 E
  • 2019 Q3 E
  • 2019 Q4 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 Q1 E
  • 2020 Q2 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-05-19 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.